Targeting immune resistance in triple-negative breast cancer
Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer
This study is exploring a new way to help treat triple-negative breast cancer by using a special antibody to make cancer cells easier for the immune system to fight, which could improve the effectiveness of existing immunotherapy treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10829923 on NIH RePORTER |
What this research studies
This research investigates a new approach to improve treatment for triple-negative breast cancer (TNBC) by targeting a specific immune evasion pathway. The study focuses on the roles of integrin αV and SOX4 proteins, which help tumor cells resist destruction by the immune system. By using a blocking antibody against integrin αVβ6, the researchers aim to enhance the effectiveness of immunotherapy, making TNBC cells more susceptible to immune attack. The research includes preclinical models to evaluate the potential benefits of this treatment strategy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer who have not responded to current immunotherapy treatments.
Not a fit: Patients with other types of breast cancer or those who have already benefited from existing immunotherapies may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for patients with triple-negative breast cancer.
How similar studies have performed: Previous research has shown promise in targeting immune evasion pathways in cancer, suggesting that this approach could be a viable strategy.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Wucherpfennig, Kai W — Dana-Farber Cancer Inst
- Study coordinator: Wucherpfennig, Kai W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.